Cargando…

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab

Detalles Bibliográficos
Autores principales:	Shoumariyeh, Khalid, Jung, Johannes, Rassner, Michael, Dold, Sandra Maria, Riebl, Veronika, Pantic, Milena, Herget, Georg, Marks, Reinhard, Lübbert, Michael, Wäsch, Ralph, Engelhardt, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116235/ https://www.ncbi.nlm.nih.gov/pubmed/33712868 http://dx.doi.org/10.1007/s00277-021-04490-3

Ejemplares similares

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients
por: Riebl, Veronika, et al.
Publicado: (2021)

Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures
por: Engelhardt, Monika, et al.
Publicado: (2021)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
por: Rassner, Michael, et al.
Publicado: (2021)

Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab
por: Strüßmann, Tim, et al.
Publicado: (2022)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
por: Santini, Valeria, et al.
Publicado: (2021)

Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)
por: Klocke, Heather, et al.
Publicado: (2020)

T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report
por: Park, Sungwoo, et al.
Publicado: (2023)

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Fedorov, Kateryna, et al.
Publicado: (2023)

Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma
por: Nakamura, Ayano, et al.
Publicado: (2021)

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
por: Wäsch, Ralph, et al.
Publicado: (2023)

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
por: Mistry, Jayna J, et al.
Publicado: (2021)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
por: Becker, Heiko, et al.
Publicado: (2020)

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
por: Javorniczky, Nora Rebeka, et al.
Publicado: (2023)

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
por: Maravalle, Denise, et al.
Publicado: (2022)

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
por: Engelhardt, Monika, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Greil, Christine, et al.
Publicado: (2021)

Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis
por: Rettig, Andrés R., et al.
Publicado: (2021)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
por: Bahlis, Nizar J., et al.
Publicado: (2021)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
por: Mandhan, Nikeeta, et al.
Publicado: (2021)

Validation of the Revised Myeloma Comorbidity Index and other comorbidity scores in a multicenter German study group multiple myeloma trial
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Daratumumab‐based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia
por: Liberatore, Carmine, et al.
Publicado: (2023)

Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Efficacy of Decitabine and Venetoclax as Salvage and Bridge Therapy to Haploidentical Hematopoietic Stem Cell Transplantation in a Multiresistant Acute Myeloid Leukemia Patient
por: Serio, Bianca, et al.
Publicado: (2022)

FRI645 A Case Of Diabetic Ketoacidosis After Initiation Of Decitabine And Venetoclax Chemotherapy
por: Maini, Rohan, et al.
Publicado: (2023)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Low‐dose decitabine plus venetoclax is safe and effective as post‐transplant maintenance therapy for high‐risk acute myeloid leukemia and myelodysplastic syndrome
por: Wei, Yunxiong, et al.
Publicado: (2021)

Potential role of daratumumab in the treatment of multiple myeloma
por: Khagi, Yulian, et al.
Publicado: (2014)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
por: Plesner, Torben
Publicado: (2021)

New developments in the treatment of multiple myeloma – clinical utility of daratumumab
por: McEllistrim, Cian, et al.
Publicado: (2017)

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
por: Greil, Christine, et al.
Publicado: (2019)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d04dfmcsab3u341qfmrnbkjjh2